Scholar Rock, LLC

For big pharma companies who want a major stake in the ballooning obesity market, opportunities to license in a mid-stage asset are dwindling. Roche claimed one of the top unlicensed candidates on 12

The European Medicines Agency was this week deciding whether the planned EU marketing authorization applications (MAAs) for three investigational products deserved accelerated assessments – apitegroma

“If I think of my well-functioning development machine as let’s say a V12 engine with 12 cylinders, cylinders four, five, six and seven and at different times eight are in Hyderabad.” That’s how Novar

Biogen’s spinal muscular atrophy (SMA) drug Spinraza (nusinersen) had an unexpected uptick in sales in the fourth quarter of 2024 after a few years of declining sales in the face of competing medicine